Driving ROI: The Business Case For A Real-Time Clinical Trial Oversight Solution

A 20% sample collection error rate. Three thousand queries per study. Months lost to manual reconciliation before a database can even be locked. These are not outliers; they are the predictable consequences of managing biological samples with paper forms and disconnected systems. The downstream effects ripple across the entire trial. An independent ROI analysis found that shifting to real-time oversight in a Phase 3 oncology trial could deliver $3.1 million in immediate savings and a total study value of $24.9 million. This return exceeds 2,000%.

If sample management inefficiency is quietly eroding your trial's timeline and data quality, this paper provides a framework to quantify exactly what it's costing you, and what addressing it is worth.